Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Bristol-Myers Squibb Hepatitis C Therapy Opens Up Combination Options

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

In the race for new hepatitis C therapies, Bristol-Myers Squibb (NYSE: BMY  ) is done courting Gilead (NASDAQ: GILD  ) , maker of the first all-oral treatment for hepatitis C Sovaldi (sofosbuvir.)

Following Gilead's approval of Sovaldi, Bristol-Myers has long been trying to convince Gilead to join forces in a combination drug of sofosbuvir and Bristol-Myers' daclatasvir. However, Gilead has resisted a partnership and has maintained its potential combination drugs in-house.

With daclatasvir's approval pending in Europe, Bristol-Myers has garnered the confidence to break away from a possible partnership and piggyback its use with Gilead's sofosbuvir potentially off-label. Medically, the combination of daclatasvir and sofosbuvir has shown stellar results. Studies have shown that 12-week combination therapy cleared 100% of the virus in a study of 41 patients who were refractory to prior treatments of Incivek and Victrelis, gold standard treatments for hepatitis C .

Gilead's in-house sofosbuvir-ledipasvir combination has proven that it offers potentially better results for genotype 1, the major genotype of HCV. However, Bristol-Myers' proposed daclatasvir and sofosbuvir combination looks like it is preferential for the less prevalent, but still significant, population of patients with genotype 3. What it lacks in reach of patient population, Bristol-Myers has made up with in time – likely the European approval of daclatasvir will come before approval of Gilead's in-house combination.

For a market that analysts estimate to be worth $100 billion , there are multiple ways to slice the pie for the various players. That pie, however, may be more valuable to Bristol-Myers than Gilead. The former New York company recently backed out of the diabetes market after the sale of a $4.3 billion stake with AstraZeneca. With a narrower focus on antivirals, cancer treatments, and specialty medications, Bristol-Myers needs to dominate each one even more to reinforce its lofty valuation.

Nonetheless, Gilead is positioned to take the biggest stake of that market with the blockbuster Sovaldi priced at $84,000 per treatment course with estimated $8.22 billion in sales by 2016 . Gilead's impending combination therapies coming later this year can only help, so it is no wonder that the giant is not willing to partner with Bristol-Myers.

The two companies are far from the only players in the quickly crowding field, however. Johnson & Johnson (NYSE: JNJ  ) actually gained FDA approval for its oral medication Olysio a month before Gilead's Sovaldi won approval. However, Johnson & Johnson's therapy targets a much smaller patient population based on efficacy with particular genotypes of hepatitis C.

Once daclatasvir gains approval, it will allow for off-label combinations for doctors satisfied with the existing studies on the combination. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has already approved the use of a sofosbuvir-daclatasvir combination for compassion use in patients with genotype 1 who would otherwise be expected to die within a year. Executives at Bristol-Myers are hopeful that the movement in Europe will allow them to leverage the same in the United States. As such, while Gilead will still likely retain dominance for the prevalent genotype 1 hepatitis C market, Bristol-Myers may be able to effectively treat patients suffering from genotype 3. This would give the company a nice share of the market as well.

Incredible biotechs to revolutionize your portfolio
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2804263, ~/Articles/ArticleHandler.aspx, 9/1/2015 8:31:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Amy Ho

Medical provider. Emergency medicine. Interest in biotech. Background in online retail.

Today's Market

updated Moments ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:02 PM
BMY $58.20 Down -1.27 -2.14%
Bristol-Myers Squi… CAPS Rating: ****
GILD $101.49 Down -3.58 -3.41%
Gilead Sciences CAPS Rating: *****
JNJ $92.09 Down -1.89 -2.01%
Johnson & Johnson CAPS Rating: ****